February 5, 2021
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications. Read more
Reading level: College
EurekAlert!, the online, global news service operated by AAAS, the science society
Please Give Us Feedback!

Why are you reading this article? (check all that apply)







How do you feel about science?







Send Feedback
Free science fair projects.